journal
MENU ▼
Read by QxMD icon Read
search

Lung Cancer: Journal of the International Association for the Study of Lung Cancer

journal
https://www.readbyqxmd.com/read/28089229/immune-checkpoint-inhibition-in-malignant-mesothelioma-does-it-have-a-future
#1
EDITORIAL
Aaron Scott Mansfield
No abstract text is available yet for this article.
January 9, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28095982/what-is-the-optimal-radiotherapy-schedule-for-limited-stage-small-cell-lung-cancer
#2
EDITORIAL
Ben Slotman
Thoracic radiotherapy plays an important role in the treatment of limited disease SCLC. Best results are obtained with twice daily (BID) radiotherapy, starting early and given concurrently with chemotherapy. At ASCO, 2016, Faivre-Finn and colleagues presented the results of the CONVERT trial, comparing such a scheme with once daily radiotherapy to a higher dose. There was no statistically significant difference in survival between the two arms. Although the publication of the study is still awaited, this editorial puts the available data in perspective and draws some important conclusions...
January 4, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28062090/oligometastatic-non-small-cell-lung-cancer-where-do-we-go-next
#3
EDITORIAL
Nauman Malik, David Palma
No abstract text is available yet for this article.
December 26, 2016: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27894607/exosomes-in-lung-cancer-liquid-biopsies-two-sides-of-the-same-coin
#4
LETTER
Christian Rolfo, Marco Giallombardo, Pablo Reclusa, Rafael Sirera, Marc Peeters
No abstract text is available yet for this article.
November 18, 2016: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27863911/crizotinib-for-ros1-patients-one-small-step-in-biomarker-testing-one-giant-leap-for-advanced-nsclc-patients
#5
EDITORIAL
Oscar Juan, Sanjay Popat
No abstract text is available yet for this article.
November 11, 2016: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28024701/a-comprehensive-analysis-of-clinical-outcomes-in-lung-cancer-patients-harboring-a-met-exon-14-skipping-mutation-compared-to-other-driver-mutations-in-an-east-asian-population
#6
Chien-Hung Gow, Min-Shu Hsieh, Shang-Gin Wu, Jin-Yuan Shih
INTRODUCTION: Recurrent somatic splice-site alterations at MET exon 14 (MET(Δ14)), which result in exon skipping and MET proto-oncogene, receptor tyrosine kinase (MET) activation, have been characterised. However, their demographic features and clinical outcomes in East Asian lung cancer patients have yet to be determined. METHODS: A one-step reverse transcription-polymerase chain reaction (RT-PCR), using RNA samples from 850 East Asian lung cancer patients, was performed in order to detect MET(Δ14) and five other major driver mutations, including those in the EGFR, KRAS, ALK, HER2, and ROS1 genes...
January 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28024700/defining-outcomes-of-patients-with-clinical-stage-i-small-cell-lung-cancer-upstaged-at-surgery
#7
Daniel C Thomas, Brian N Arnold, Joshua E Rosen, Michelle C Salazar, Justin D Blasberg, Frank C Detterbeck, Daniel J Boffa, Anthony W Kim
BACKGROUND: A proportion of patients with clinical stage I small cell lung cancer (SCLC) will be upstaged following surgical resection. The existing data regarding the management of upstaged SCLC patients and guidelines for their treatment remains sparse. The primary objective was to describe the impact of pathologic upstaging following surgical resection. METHODS: The National Cancer Database was queried for patients with clinical stage I SCLC (cT1-2a,N0,M0) who underwent resection with curative intent followed by adjuvant therapy, excluding patients who underwent surgery alone...
January 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28024699/temporal-patterns-of-care-and-outcomes-of-non-small-cell-lung-cancer-patients-in-the-united-states-diagnosed-in-1996-2005-and-2010
#8
Filip Kaniski, Lindsey Enewold, Anish Thomas, Shakuntala Malik, Jennifer L Stevens, Linda C Harlan
INTRODUCTION: Lung cancer remains a common and deadly cancer in the United States. This study evaluated factors associated with stage-specific cancer therapy and survival focusing on temporal trends and sociodemographic disparities. METHODS: A random sample (n=3,318) of non-small cell lung cancer (NSCLC) patients diagnosed in 1996, 2005 and 2010, and reported to the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) program was analyzed...
January 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28024698/interpreting-survival-data-from-clinical-trials-of-surgery-versus-stereotactic-body-radiation-therapy-in-operable-stage-i-non-small-cell-lung-cancer-patients
#9
Pamela Samson, Kathleen Keogan, Traves Crabtree, Graham Colditz, Stephen Broderick, Varun Puri, Bryan Meyers
OBJECTIVES: To identify the variability of short- and long-term survival outcomes among closed Phase III randomized controlled trials with small sample sizes comparing SBRT (stereotactic body radiation therapy) and surgical resection in operable clinical Stage I non-small cell lung cancer (NSCLC) patients. PATIENTS AND METHODS: Clinical Stage I NSCLC patients who underwent surgery at our institution meeting the inclusion/exclusion criteria for STARS (Randomized Study to Compare CyberKnife to Surgical Resection in Stage I Non-small Cell Lung Cancer), ROSEL (Trial of Either Surgery or Stereotactic Radiotherapy for Early Stage (IA) Lung Cancer), or both were identified...
January 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28024697/reversal-of-platinum-drug-resistance-by-the-histone-deacetylase-inhibitor-belinostat
#10
Kenneth Kin-Wah To, Wing-Sum Tong, Li-Wu Fu
OBJECTIVES: To investigate and elucidate the mechanism for the potentiation of cisplatin anticancer activity by belinostat in platinum (Pt)-resistant lung cancer cells. MATERIALS AND METHODS: Combination of cisplatin and belinostat was investigated in two pairs of parental and cisplatin-resistant non-small cell lung cancer (NSCLC) cell lines. The Pt-resistant cell models exhibited overexpression of the efflux transporter ABCC2 and enhanced DNA repair capacity. Cellular accumulation of cisplatin and extent of DNA platination were measured by inductively coupled plasma optical emission spectrometer...
January 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28024696/pik3ca-mutations-as-prognostic-factor-in-squamous-cell-lung-carcinoma
#11
Marc McGowan, Aleksandra Silye Hoven, Marius Lund-Iversen, Steinar Solberg, Åslaug Helland, Fred R Hirsch, Odd Terje Brustugun
OBJECTIVES: Mutation in the PIK3CA gene is reported frequent in squamous cell carcinomas of the lung, but its potential prognostic role is still obscure. We have studied the prognostic importance of PIK3CA mutations as well as the relation to other markers in a large number of early stage lung cancers of squamous carcinoma subtype. PATIENTS AND METHODS: Tumour tissue was obtained from 308 consecutively operated lung cancer patients with squamous cell carcinoma in the period 2003-2013...
January 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28024695/tumor-b7-h3-cd276-expression-and-smoking-history-in-relation-to-lung-adenocarcinoma-prognosis
#12
Kentaro Inamura, Yusuke Yokouchi, Maki Kobayashi, Rie Sakakibara, Hironori Ninomiya, Sophia Subat, Hiroko Nagano, Kimie Nomura, Sakae Okumura, Tomoko Shibutani, Yuichi Ishikawa
OBJECTIVES: Compared with non-smoking counterparts, smoking-associated lung cancers have a higher mutational load, resulting in the creation of more tumor neoantigens and increased immunogenicity. B7-H3 (also known as CD276) belongs to a family of immune modulators that includes PD-1 and PD-L1 (also known as B7-H1 or CD274). Considering the evidence that PD-L1 inhibitors have been shown to be more effective against lung cancer in smokers, we herein examined the prognostic interaction of tumor B7-H3 expression level with smoking history in lung adenocarcinoma patients...
January 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28024694/the-diagnostic-performance-of-routinely-acquired-and-reported-computed-tomography-imaging-in-patients-presenting-with-suspected-pleural-malignancy
#13
Selina Tsim, David B Stobo, Laura Alexander, Caroline Kelly, Kevin G Blyth
OBJECTIVES: Contrast-enhanced computed tomography (CT) provides essential cross-sectional imaging data in patients with suspected pleural malignancy (PM). The performance of CT in routine practice may be lower than in previously reported research. We assessed this relative to 'real-life' factors including use of early arterial-phase contrast enhancement (by CT pulmonary angiography (CTPA)) and non-specialist radiology reporting. MATERIALS AND METHODS: Routinely acquired and reported CT scans in patients recruited to the DIAPHRAGM study (a prospective, multi-centre observational study of mesothelioma biomarkers) between January 2014 and April 2016 were retrospectively reviewed...
January 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28024693/the-race-to-target-met-exon-14-skipping-alterations-in-non-small-cell-lung-cancer-the-why-the-how-the-who-the-unknown-and-the-inevitable
#14
REVIEW
Thanyanan Reungwetwattana, Ying Liang, Viola Zhu, Sai-Hong Ignatius Ou
A number of small molecule tyrosine kinase inhibitors (TKIs) have now been approved for the treatment of non-small cell lung cancers (NSCLC), including those targeted against epidermal growth factor receptor, anaplastic lymphoma kinase, and ROS1. Despite a wealth of agents developed to target the receptor tyrosine kinase, MET, clinical outcomes have as yet been disappointing, leading to pessimism about the role of MET in the pathogenesis of NSCLC. However, in recent years, there has been a renewed interest in MET exon 14 alterations as potential drivers of lung cancer...
January 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28024692/synchronous-occurrence-of-squamous-cell-carcinoma-transformation-and-egfr-exon-20-s768i-mutation-as-a-novel-mechanism-of-resistance-in-egfr-mutated-lung-adenocarcinoma
#15
Lucia Longo, Maria Cecilia Mengoli, Federica Bertolini, Stefania Bettelli, Samantha Manfredini, Giulio Rossi
The occurrence of secondary EGFR mutation T790M in exon 20 and histologic "transformation" are common mechanisms underlying resistance to EGFR first- or second-generation tyrosine kinase inhibitors (TKI). We describe here on a hitherto unreported mechanism of EGFR TKI resistance synchronously combining squamous-cell carcinoma change and occurrence of the EGFR exon 20 S768I secondary mutation in a 43 year-old woman with stage IV adenocarcinoma harbouring EGFR exon 21 L858R mutation. After 8 months of response to gefitinib, the patient experienced EGFR TKI resistance and died of leptomeningeal neoplastic dissemination...
January 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28024691/detection-of-alk-rearrangements-in-4002-russian-patients-the-utility-of-different-diagnostic-approaches
#16
Irina Demidova, Viacheslav Grinevich, Ashot Avdalian, Evgeny Imyanitov, Marina Gikalo, Nikita Savelov, Inna Novikova, Olga Samuilenkova, Vladislav Tiurin, Elena Ulianova, Ilya Tsimafeyeu, Sergey Tjulandin
BACKGROUND: Clinical guidelines highly recommended the detection of potentially targetable genetic aberrations such as anaplastic lymphoma kinase (ALK) rearrangements in patients with non-small cell lung cancer (NSCLC). Few methods, such as the ALK break apart FISH assay and IHC for ALK protein, are approved for routine diagnostics. However, some challenges exist in selecting the most reliable, robust and cost-effective algorithm, especially for large-scale screening of NSCLC patients...
January 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28024690/trends-in-stereotactic-body-radiation-therapy-for-stage-i-small-cell-lung-cancer
#17
John M Stahl, Christopher D Corso, Vivek Verma, Henry S Park, Sameer K Nath, Zain A Husain, Charles B Simone, Anthony W Kim, Roy H Decker
OBJECTIVES: We aimed to report trends in stereotactic body radiation therapy (SBRT) utilization, dose prescriptions, and chemotherapy administration for stage I small cell lung cancer (SCLC) in the United States. MATERIALS AND METHODS: The National Cancer Data Base (NCDB) was used to identify patients with cT1-2 N0 SCLC treated with SBRT between 2004 and 2013. Trends in SBRT use and dose prescription were analyzed over time. Multivariable logistic regression was used to determine factors associated with the administration of chemotherapy with SBRT...
January 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28024689/alk-testing-in-non-small-cell-lung-cancer-nsclc-immunohistochemistry-ihc-and-or-fluorescence-in-situ-hybridisation-fish-statement-of-the-germany-society-for-pathology-dgp-and-the-working-group-thoracic-oncology-aio-of-the-german-cancer-society-e-v-stellungnahme
#18
M von Laffert, P Schirmacher, A Warth, W Weichert, R Büttner, R M Huber, J Wolf, F Griesinger, M Dietel, Ch Grohé
The EML4-ALK pathway plays an important role in a significant subset of non-small cell lung cancer patients. Treatment options such as ALK tyrosine kinase inhibitors lead to improved progression free survival and overall survival. These therapeutic options are chosen on the basis of the identification of the underlying genetic signature of the EML-ALK translocation. Efficient and easily accessible testing tools are required to identify eligible patients in a timely fashion. While FISH techniques are commonly used to detect this translocation, the broad implementation of this type of ALK testing into routine diagnostics is not optimal due to technical, structural and financial reasons...
January 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27721121/withdrawn-tumor-b7-h3-cd276-expression-and-smoking-history-in-relation-to-lung-adenocarcinoma-prognosis
#19
Kentaro Inamura, Yusuke Yokouchi, Maki Kobayashi, Rie Sakakibara, Hironori Ninomiya, Sophia Subat, Hiroko Nagano, Kimie Nomura, Sakae Okumura, Tomoko Shibutani, Yuichi Ishikawa
The Publisher regrets that this article is an accidental duplication of an article that has already been published in The Journal of Lung Cancer - http://dx.doi.org/10.1016/j.lungcan.2016.11.013. Please see online announcement for additional details. The duplicate article has therefore been withdrawn. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.
December 10, 2016: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27987596/the-challenge-of-molecular-testing-for-clinical-trials-in-advanced-non-small-cell-lung-cancer-patients-analysis-of-a-prospective-database
#20
Anniek Vrancken, Stefanie Lepers, Liesbet Peeters, Christel Oyen, Christophe Dooms, Kristiaan Nackaerts, Eric Verbeken, Isabelle Wauters, Birgit Weynand, Johan Vansteenkiste
OBJECTIVES: Molecular testing has become important in the biomarker program of clinical trials for advanced non-small lung cancer (NSCLC). These tissue samples often have to be analyzed in a central laboratory. We evaluated the turnaround time and possible delay in start of therapy in this process and how often testing resulted in inclusion in a clinical trial. METHODS: We reviewed our prospective database on all molecular testing cases for clinical trial suitability in patients with advanced NSCLC between March 1, 2011 and October 31, 2014...
December 2016: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
journal
journal
29732
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"